基于患者报告的疾病活动度评分(PDAS)在日本类风湿关节炎患者登记数据库(NinJa)中的评估
该研究分析2022版日本风湿病数据库(NinJa)中11983例类风湿关节炎患者,计算PDAS1并与DAS28(ESR)、CDAI等指标做相关及回归分析,采用倾向性评分匹配比较不同DMARDs。PDAS1与DAS28(ESR)(R=0.89)及CDAI强相关,71.8%患者达PDAS1定义的缓解,RF阳性者PDAS1更高;匹配后IL-6抑制剂组PDAS1低于TNF抑制剂组,反映患者总体评估较低。
要点
- PDAS1与DAS28(ESR)(R=0.89)及CDAI强相关,可用于评估疾病活动度。
- 71.8%患者达PDAS1定义的缓解,与DAS28和CDAI缓解高度一致。
- 倾向性评分匹配后,IL-6抑制剂组PDAS1低于TNF抑制剂组,反映患者总体评估较低。
核心结论
- PDAS1是评估RA患者疾病活动度和功能状态的可靠有用工具,尤其从患者报告结局(PROs)角度。
- PDAS1可用于RA患者的临床研究。
研究设计与样本
- 分析2022版日本风湿病数据库(NinJa)的临床数据,纳入11983例患者。
- 对每例患者计算PDAS1,进行相关分析和多元回归分析,并用倾向性评分匹配比较不同DMARDs治疗的患者。
主要发现
- PDAS1与DAS28(ESR)强相关(R=0.89,P<2.2×10^16),与CDAI亦相关,提示其评估疾病活动度的效用。
- 71.8%患者达到PDAS1定义的缓解,与DAS28和CDAI缓解高度一致。
- PDAS1与血清RF滴度显著相关(R=0.25,P<0.001),RF阳性患者PDAS1评分更高。
- 倾向性评分匹配比较显示,IL-6抑制剂治疗患者PDAS1低于TNF抑制剂治疗患者,反映患者总体评估较低。
关键数值与推荐
- PDAS1与DAS28(ESR)的相关系数R=0.89(P<2.2×10^16)。
- PDAS1与血清RF滴度的相关系数R=0.25(P<0.001)。
- 71.8%患者达到PDAS1定义的缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patient-reported outcomes (PROs) should be regarded as an important factor in the management of rheumatic diseases. The patient-based disease activity score (PDAS) was developed as a clinically reliable composite measure for evaluating PROs in RA patients. To replicate and further characterize PDAS, we analysed PDAS and its clinical relevancy in the National Database of Rheumatic Diseases in Japan (NinJa). METHODS: Clinical data from the 2022 version of NinJa were analysed. PDAS1 was calculated for each patient, and statistical analyses, including correlation analyses and multiple regression analysis, were conducted to evaluate the relationship between PDAS1 and other clinical measures. Propensity score (PS) matching was used to compare patients treated with different types of DMARDs. RESULTS: The number of included patients was 11 983. PDAS1 demonstrated strong correlations with DAS28(ESR) (R = 0.89, P < 2.2 × 1016) and Clinical Disease Activity Index (CDAI), indicating its utility in assessing disease activity. The majority of patients (71.8%) achieved PDAS1-defined remission, aligning closely with DAS28 and CDAI remission. PDAS1 was significantly associated with serum RF titres (R = 0.25, P < 0.001), and RF-positive patients exhibited higher PDAS1 scores. Notably, PS-matched comparison revealed that PDAS1 was lower in patients treated with IL-6 inhibitors, compared with those treated with TNF inhibitors, reflecting differences in lower patient global assessment. CONCLUSION: PDAS1 is a reliable and useful tool for evaluating both disease activity and the functional state of RA patients, particularly from the perspective of PROs. Additionally, PDAS1 can be used for conducting clinical studies in RA patients.
引用
- Shoda H, Matsui T, Tohma S, et al. Evaluation of patient-based disease activity score (PDAS) in the Japanese rheumatoid arthritis patient registry (NinJa registry). Rheumatology (Oxford). 2025. PMID: 39908454. doi:10.1093/rheumatology/keaf067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。